PRecision Medicine in Segregating Endotypes in preterm birth (PRoMISE)
Recurrent preterm birth remains a persistent problem, and almost half of women with a prior preterm birth deliver before 37 weeks during subsequent pregnancies. Providers often offer pregnant women with a history of preterm birth 17 hydroxyprogesterone caproate (17OHPC), in order to improve maternal and neonatal well being. PRoMISE will analyze if 17OHPC yields genetic, microbial, and metabolic markers for women that respond differently to the drug. Considering only 30-35% of women experience a term pregnancy on 17OHPC, the identification of these biomarkers provides a valuable tool to effectively screen responsive candidates in the future. The study comprises 150 women with a prior spontaneous preterm birth delivering within the University of Pennsylvania health system. Participants can choose to take 17OHPC during the course of their pregnancy or decide not to receive the drug. Participants will come to two study visits, and researchers will collect samples of cervical cells, vaginal fluid, and blood. PRoMISE allows study participants to assist researchers in revealing the efficacy of 17OHPC and contribute to a better understanding of the origins of preterm birth.
Dr. Michal Elovitz